替奈普酶与阿替普酶及急性缺血性卒中治疗时间比较
该回顾性队列研究基于美国心脏协会Get With The Guidelines-Stroke注册数据库(2020年7月1日至2022年6月30日),纳入133 228例接受静脉溶栓的成人缺血性卒中患者,其中13 988例(10.5%)接受替奈普酶、119 240例(89.5%)接受阿替普酶。主要终点为直接到院患者的门-针时间和转院患者的门-入-出时间。结果显示替奈普酶组平均门-针时间较阿替普酶组缩短3.13分钟(95%CI -3.84至-2.42),门-针时间≤30分钟的比例更高(29.9% vs 20.4%;aOR 1.34)。转院患者中替奈普酶组门-入-出时间亦更短(-5.94分钟)。结论提示替奈普酶具有工作流程优势,支持更广泛使用。
要点
- 在133 228例静脉溶栓的急性缺血性卒中患者中,替奈普酶组平均门-针时间47.0分钟,阿替普酶组52.7分钟,校正后平均差-3.13分钟(95%CI -3.84至-2.42)。
- 替奈普酶组门-针时间≤30分钟的比例为29.9%(2955/9893),阿替普酶组为20.4%(14 781/72 539),aOR 1.34(95%CI 1.25-1.44)。
- 替奈普酶组门-针时间≤45分钟(58.3% vs 48.6%;aOR 1.24)和≤60分钟(77.5% vs 70.7%;aOR 1.25)的比例均更高。
- 在可能适合机械取栓的转院患者中,替奈普酶组门-入-出时间较阿替普酶组缩短5.94分钟(95%CI -9.10至-2.77)。
- 研究期间由阿替普酶转换为替奈普酶的医院,转换后门-针时间较转换前缩短1.52分钟(95%CI -2.88至-0.15)。
适用人群与场景
- 美国医院中接受静脉溶栓的成人缺血性卒中患者,数据来自Get With The Guidelines-Stroke注册,2020年7月1日至2022年6月30日。
- 直接到院患者用于门-针时间分析;溶栓后转院患者用于门-入-出时间分析;溶栓后接受机械取栓患者用于门-穿刺等血管内工作流程指标分析。
诊断标准与关键阈值
- 原文未提及
处置流程与药物剂量
- 原文未提及具体药物剂量、给药途径、频次或目标值。
红旗征与不能漏的情况
- 原文未提及
研究设计与关键结果
- 研究类型:基于美国心脏协会Get With The Guidelines-Stroke注册的回顾性队列研究,纳入133 228例接受静脉溶栓的成人缺血性卒中患者(平均年龄68.3岁,女性48.2%,NIHSS中位数7分)。
- 暴露:13 988例(10.5%)接受替奈普酶,119 240例(89.5%)接受阿替普酶。
- 主要终点:替奈普酶组平均门-针时间47.0分钟 vs 阿替普酶组52.7分钟,校正后平均差-3.13分钟(95%CI -3.84至-2.42)。
- 门-针时间≤30分钟比例:替奈普酶组29.9%(2955/9893)vs 阿替普酶组20.4%(14 781/72 539),aOR 1.34(95%CI 1.25-1.44);≤45分钟比例58.3% vs 48.6%(aOR 1.24,95%CI 1.17-1.32);≤60分钟比例77.5% vs 70.7%(aOR 1.25,95%CI 1.17-1.33)。
- 转院患者门-入-出时间:替奈普酶组108.3分钟 vs 阿替普酶组114.1分钟,校正后平均差-5.94分钟(95%CI -9.10至-2.77)。
- 接受机械取栓患者中,替奈普酶组门-动脉穿刺、门-器械释放和门-再灌注时间均较短(原文未提供具体数值)。
- 研究期间由阿替普酶转换为替奈普酶的医院,转换后门-针时间51.1分钟 vs 转换前52.7分钟,校正后平均差-1.52分钟(95%CI -2.88至-0.15)。
证据类型、等级与局限
- 证据类型:基于全国性注册数据库的回顾性队列研究。
- 局限:观察性设计,原文未提及随机化或盲法;可能存在未测量混杂;原文未报告证据等级或推荐强度。
对床旁实践的改变
- 对于急性缺血性卒中静脉溶栓患者,选择替奈普酶可能缩短门-针时间并提高时间窗内溶栓达标率,支持在适合人群中更广泛使用替奈普酶。
- 对于溶栓后转院行机械取栓的患者,替奈普酶可能缩短门-入-出时间,有助于加快转运。
- 原文未提及具体适用与不适用人群的限定,实践改变需结合当地流程和患者个体情况。
指南或共识出处
- 原文未提及
以上提炼依据论文摘要(全文未开放获取,或许可不允许翻译转载);全文请点「阅读原文」。
英文原文(摘要)· 点击展开
IMPORTANCE: Tenecteplase is an alternative to alteplase for intravenous thrombolysis in acute ischemic stroke given its simplified administration and comparable safety and efficacy. However, its impact on workflow metrics that may affect clinical outcomes, such as door-to-needle and door-in-door-out times, has not been well-characterized.
OBJECTIVE: To compare door-to-needle and door-in-door-out times between tenecteplase-treated and alteplase-treated patients with acute ischemic stroke in US hospitals.
DESIGN, SETTING, AND PARTICIPANTS: This cohort study used data from the American Heart Association's Get With The Guidelines-Stroke registry between July 1, 2020, and June 30, 2022. The analysis included adult patients with ischemic stroke who received intravenous thrombolysis. Data analysis was conducted from August to November 2023.
EXPOSURE: Tenecteplase or alteplase treatment in a consecutive series of patients with ischemic stroke.
MAIN OUTCOMES AND MEASURES: Primary outcomes were door-to-needle time among patients who arrived directly to the reporting hospital and door-in-door-out time among those transferred after thrombolytic administration. Secondary outcomes were door-to-puncture and other endovascular workflow metrics among patients treated with thrombectomy after thrombolysis. Generalized linear mixed models were used to assess the association between thrombolytic treatment and workflow time intervals outcomes.
RESULTS: Of 133 228 thrombolysis-treated patients (mean [SD] age, 68.3 [14.8] years; 64 173 female [48.2%]; median [IQR] National Institutes of Health Stroke Scale score, 7 [3-14]), 13 988 (10.5%) received tenecteplase, and 119 240 (89.5%) received alteplase. The mean (SD) door-to-needle time was significantly shorter with tenecteplase vs alteplase (47.0 [26.8] vs 52.7 [28.0] minutes; adjusted mean difference, -3.13 minutes; 95% CI, -3.84 to -2.42 minutes). Door-to-needle time 30 minutes or less occurred more frequently with tenecteplase than with alteplase (2955 of 9893 patients [29.9%] vs 14 781 of 72 539 patients [20.4%]; adjusted odds ratio [aOR], 1.34; 95% CI, 1.25 to 1.44), as did door-to-needle time 45 minutes or less (5766 of 9893 patients [58.3%] vs 35 238 of 72 539 patients [48.6%]; aOR, 1.24; 95% CI, 1.17 to 1.32) and 60 minutes or less (7670 of 9893 patients [77.5%] vs 51 282 of 72 539 patients [70.7%]; aOR, 1.25; 95% CI, 1.17 to 1.33). Among transferred patients likely eligible for mechanical thrombectomy, mean (SD) door-in-door-out times were shorter for tenecteplase vs alteplase (108.3 [31.6] vs 114.1 [32.0] minutes; adjusted mean difference, -5.94 minutes; 95% CI, -9.10 to -2.77 minutes). Among patients receiving thrombectomy, shorter times were observed in the tenecteplase group for door-to-arterial puncture, door-to-device deployment, and door-to-reperfusion. Hospitals that transitioned to tenecteplase during the study period had faster door-to-needle time times after vs before the switch (mean [SD], 51.1 [12.1] vs 52.7 [10.8] minutes; adjusted mean difference, -1.52 minutes; 95% CI, -2.88 to -0.15 minutes).
CONCLUSIONS AND RELEVANCE: In this analysis of a large nationwide registry, tenecteplase was associated with faster door-to-needle and door-in-door-out times than alteplase. These workflow advantages provide support for broader use of tenecteplase for stroke thrombolysis.
参考来源
- Warach SJ, Weber JM, Alhanti B, et al. Tenecteplase vs Alteplase and Time to Treatment for Acute Ischemic Stroke. JAMA Netw Open. 2026. PMID: 42440314. doi:10.1001/jamanetworkopen.2026.23260
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。